Piperidinylamino-thieno[2,3-D] pyrimidine compounds

A method of treating systemic hypertension, comprising administering to a patient in need thereof a composition comprising a compound of formula II or III;

• wherein formula II is represented by
• wherein
• R1 is selected from the group consisting of halo, lower alkyl, cyano, and trihalomethyl;
• each R2 is independently hydrogen, halo, cyano, trihalomethyl, lower alkoxy, carboxylate, an amide, or a sulfonyl group;
• and
• n is 1 or 2, provided that when n is 1, R2 is not hydrogen, and when n is 2, both R2 groups are not hydrogen;
• or a pharmaceutically acceptable salt thereof;
• and
• formula III is represented by
• wherein
• X is halo;
• R3 is hydrogen, halo, cyano, or trihalomethyl;
• and
• n is 1 or 2, provided that when n is 1, R3 is not hydrogen, and when n is 2, both R3 groups are not hydrogen;
• or a pharmaceutically acceptable salt thereof.

A method of treating a disorder selected from the group consisting of migraine and pulmonary arterial hypertension, comprising administering to a patient in need thereof a composition comprising a compound of formula II or III or its salt in an amount effective to treat the disorder;

• wherein formula II is represented by
• wherein
• R1 is selected from the group consisting of halo, lower alkyl, cyano, and trihalomethyl;
• each R2 is independently hydrogen, halo, cyano, trihalomethyl, lower alkoxy, carboxylate, an amide, or a sulfonyl group;
• and
• n is 1 or 2, provided that when n is 1, R2 is not hydrogen, and when n is 2, both R2 groups are not hydrogen;
• or a pharmaceutically acceptable salt thereof;
• and
• formula III is represented by
• wherein
• X is halo;
• R3 is hydrogen, halo, cyano, or trihalomethyl;
• and
• n is 1 or 2, provided that when n is 1, R3 is not hydrogen, and when n is 2, both R3 groups are not hydrogen;
• or a pharmaceutically acceptable salt thereof.